Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Vivos Therapeutics Inc (VVOS)

22 + Investors. Track Smart Money conviction in VVOS. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +3
Streak
1Q ▲
Buyers last Q
64%

Smart Money Signals — VVOS

Based on 22 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added VVOS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
22 hedge funds hold VVOS right now — the highest count in 2.5 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +10% more funds vs a year ago

fund count last 6Q
+2 new funds entered over the past year (+10% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟢

More buyers than sellers — 64% buying

9 buying5 selling
Last quarter: 9 funds were net buyers (6 opened a brand new position + 3 added to an existing one). Only 5 were sellers (2 trimmed + 3 sold completely). A clear majority buying is a strong confirmation signal.
➡️

Steady new buyers — ~6 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 4 → 8 → 1 → 6. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
📌

Mixed — 27% long-term, 41% new

27% conviction (2yr+) 32% medium 41% new
Of the 22 current holders: 6 (27%) held >2 years, 7 held 1–2 years, and 9 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💎

Buying through price weakness — shares +122%, value +31%

Value
+30%
Shares
+121%
Last quarter: funds added +122% more shares while total portfolio value only changed +31%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
⚠️

Saturation — most institutions already know this story

5 → 4 → 8 → 1 → 6 new funds/Q
New funds entering each quarter: 4 → 8 → 1 → 6. Far fewer institutions are entering now vs. a year ago. When the pool of potential new buyers shrinks this fast, future price support from institutional inflows weakens significantly.
📊

Mixed cohorts — 23% veterans, 50% new entrants

23% veterans 27% 1-2yr 50% new
Of 22 current holders: 5 (23%) held 2+ years, 6 held 1–2 years, 11 (50%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
📋

Smaller funds dominant — 9% AUM from top-100

9% from top-100 AUM funds
7 of 22 holders rank in the top 100 by AUM, but together hold only 9% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
4.1
out of 10
Moderate Exit Risk
Exit risk score 4.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — VVOS

In 2026 Q1, 9 hedge funds were net buyers of VVOS (6 opened a new position, 3 added to an existing one), while 5 reduced or exited (2 trimmed, 3 sold completely) — a 64% buyer ratio, indicating clear institutional accumulation. Net fund flow last quarter: +3 funds (more new holders than closures). Total institutional holders: 22.

Hedge Fund Ownership: VVOS

How many hedge funds hold VVOS — quarterly history vs. share price
Quarterly hedge fund ownership of VVOS vs. share price

Market Analysis: VVOS

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: VVOS

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Vivos Therapeutics Inc (VVOS) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much VVOS has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 75d ago
VVOS
-51.5%
XLV
+4.9%

VVOS outperformed XLV by -56.4% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 30d ago
VVOS
-10.8%
XLV
+6.0%

Since the filing became public, VVOS outperformed XLV by -16.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

2 top-rated funds 0 high-conviction
Consensus
2.1
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: VVOS
22 + Investors

Track Smart Money conviction in VVOS. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 22 19 15.79%
13F Shares 2M 707K 121.62%
Total Value $2M $1M 30.63%
New Positions 6 1 +5
Increased Positions 3 6 -3
Closed Positions 3 4 -1
Reduced Positions 2 3 -1
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: VVOS

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

22 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in VVOS. Verified SEC 13F-HR filings.

QUARTER:
Top 19 VVOS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Cutter & CO Brokerage, Inc. 0.03% 49,100 $140K
2 Armistice Capital, LLC 0.02% 1,115,859 $1.3M
3 Centurion Wealth Management LLC 0.01% 35,684 $42K
4 Acorn Wealth Advisors, LLC 0.01% 14,776 $17K
5 B. Riley Wealth Advisors, Inc. 0.00% 38,066 $41K
6 IHT Wealth Management, LLC 0.00% 41,061 $48K
7 XTX Topco Ltd 0.00% 25,117 $30K
8 Tower Research Capital LLC (TRC) 0.00% 7,388 $9K
9 Sequoia Financial Advisors, LLC 0.00% 24,000 $28K
10 Commonwealth Equity Services, LLC 0.00% 42,500 $50K
11 Kozak & Associates, Inc. 0.00% 49
12 Signaturefd, LLC 0.00% 547
13 Blue Trust, Inc. 0.00% 160
14 Osaic Holdings, INC. 0.00% 1,143 $1K
15 UBS Group AG 0.00% 11,046 $13K
16 BlackRock, Inc. 0.00% 27,817 $33K
17 Northwestern Mutual Wealth Management Co 0.00% 3
18 Morgan Stanley 0.00% 7
19 Citigroup Inc 0.00% 1
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Vivos Therapeutics Inc (VVOS)

What does the Smart Money Trend signal show for VVOS?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added VVOS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for VVOS?

More buyers than sellers — 64% buying: Last quarter: 9 funds were net buyers (6 opened a brand new position + 3 added to an existing one). Only 5 were sellers (2 trimmed + 3 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for VVOS holders?

Smaller funds dominant — 9% AUM from top-100: 7 of 22 holders rank in the top 100 by AUM, but together hold only 9% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held VVOS?

Mixed — 27% long-term, 41% new: Of the 22 current holders: 6 (27%) held >2 years, 7 held 1–2 years, and 9 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Vivos Therapeutics Inc (VVOS) following the 2026 Q1 hedge fund 13F filings?

As of today, VVOS has moved -10.8% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -16.8%. Since the quarter end (March 31, 2026), VVOS has gained -51.5% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →